Results 51 to 60 of about 347,568 (271)
Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies [PDF]
, 2015 The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM).
De Paepe, Boel, Zschüntzsch, Jana
core +3 more sources
Clinical and autoantibody phenotypes of juvenile dermatomyositis
Rheumatology, 2022 Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune inflammatory myositis with symmetrical proximal muscle weakness and a characteristic rash. Juvenile dermatomyositis is characterized by variable presentation and phenotypes.
O. Boyarchuk, Anna Kuka, Iryna Yuryk
semanticscholar +1 more source
Frontiers in Immunology, 2021 Juvenile dermatomyositis (JDM) is a rare autoimmune condition with insufficient biomarkers and treatments, in part, due to incomplete knowledge of the cell types mediating disease.
J. Neely +7 more
semanticscholar +1 more source
Risk factors associated with calcinosis of juvenile dermatomyositis [PDF]
, 2008 OBJETIVO: Identificar fatores de risco associados à calcinose em crianças e adolescentes com dermatomiosite juvenil. MÉTODOS: Prontuários de 54 pacientes com dermatomiosite juvenil foram estudados.
AIKAWA, Nádia E. +6 more
core +3 more sources
Resolution of calcinosis using bisphosphonates in overlap syndrome – a case report
BMC Rheumatology, 2021 Introduction Calcinosis cutis is a common complication of pediatric rheumatologic diseases. However, there is currently no consensus on first-line treatment.
Mitchell Platter +2 more
doaj +1 more source
Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers
Diagnostics, 2021 Easily accessible biomarkers are urgently needed to evaluate immune activation in Juvenile Dermatomyositis (JDM). The goal of this retrospective study is to define immunological and clinical differences between untreated JDM patients with either normal ...
Amer M. Khojah +2 more
semanticscholar +1 more source
Biomarkers in Inflammatory Myopathies – An Expanded Definition [PDF]
, 2019 Biomarkers as parameters of pathophysiological conditions can be of outmost relevance for inflammatory myopathies. They are particularly warranted to inform about diagnostic, prognostic, and therapeutic questions.
Benveniste, Olivier +2 more
core +2 more sources
ACR Open Rheumatology, 2022 The study objective was to identify differences in gene expression between treatment responders (TRs) and treatment non‐responders (TNRs) diagnosed with juvenile dermatomyositis (JDM).
C. Stingl +8 more
semanticscholar +1 more source
Nuclear matrix protein 2 antibody-positive adult dermatomyositis: a case report and review of the literature [PDF]
, 2020 Dermatomyositis is a clinically heterogenous inflammatory myopathy with unique cutaneous features. Myositis-specific antibodies can aid in diagnosis and anticipation of patient prognosis.
Cartron, Alexander M +3 more
core
Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis [PDF]
, 2016 OBJECTIVE: To compare the abbreviated Cutaneous Assessment Tool (CAT), Disease Activity Score (DAS), and Myositis Intention to Treat Activity Index (MITAX) and correlate them with the physician's 10-cm skin visual analog scale (VAS) in order to define ...
Almeida, B +9 more
core +1 more source